Tags

Type your tag names separated by a space and hit enter

Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study.
J Am Acad Child Adolesc Psychiatry. 1997 May; 36(5):685-93.JA

Abstract

OBJECTIVE

To investigate the short-term safety and efficacy of risperidone in the treatment of children and adolescents with pervasive developmental disorders.

METHOD

This was a 12-week, prospective, systematic, open-label trial that included 18 subjects (15 boys and 3 girls) with a mean age of 10.2 +/- 3.7 years. The sample included 11 subjects with autistic disorder, 3 with Asperger's disorder, 1 with childhood disintegrative disorder, and 3 with pervasive developmental disorder not otherwise specified. Fourteen subjects had comorbid mental retardation. Behavioral ratings were obtained during two baseline visits and again after 12 weeks of risperidone treatment.

RESULTS

The optimal dose of risperidone for the 18 subjects was 1.8 +/- 1.0 mg/day. On the basis of the global improvement item of the Clinical Global Impression Scale, 12 of 18 subjects were considered responders. Significant improvement was seen in measures of interfering repetitive behavior, aggression and impulsivity, and some elements of impaired social relatedness. The most common side effect was weight gain (range 10 to 35 lb).

CONCLUSIONS

These preliminary results suggest that risperidone may be effective for improving interfering behavioral symptoms in some children and adolescents with pervasive developmental disorders. Double-blind, placebo-controlled studies are needed before definitive statements of safety and efficacy can be made.

Authors+Show Affiliations

Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

9136504

Citation

McDougle, C J., et al. "Risperidone Treatment of Children and Adolescents With Pervasive Developmental Disorders: a Prospective Open-label Study." Journal of the American Academy of Child and Adolescent Psychiatry, vol. 36, no. 5, 1997, pp. 685-93.
McDougle CJ, Holmes JP, Bronson MR, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry. 1997;36(5):685-93.
McDougle, C. J., Holmes, J. P., Bronson, M. R., Anderson, G. M., Volkmar, F. R., Price, L. H., & Cohen, D. J. (1997). Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. Journal of the American Academy of Child and Adolescent Psychiatry, 36(5), 685-93.
McDougle CJ, et al. Risperidone Treatment of Children and Adolescents With Pervasive Developmental Disorders: a Prospective Open-label Study. J Am Acad Child Adolesc Psychiatry. 1997;36(5):685-93. PubMed PMID: 9136504.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. AU - McDougle,C J, AU - Holmes,J P, AU - Bronson,M R, AU - Anderson,G M, AU - Volkmar,F R, AU - Price,L H, AU - Cohen,D J, PY - 1997/5/1/pubmed PY - 1997/5/1/medline PY - 1997/5/1/entrez SP - 685 EP - 93 JF - Journal of the American Academy of Child and Adolescent Psychiatry JO - J Am Acad Child Adolesc Psychiatry VL - 36 IS - 5 N2 - OBJECTIVE: To investigate the short-term safety and efficacy of risperidone in the treatment of children and adolescents with pervasive developmental disorders. METHOD: This was a 12-week, prospective, systematic, open-label trial that included 18 subjects (15 boys and 3 girls) with a mean age of 10.2 +/- 3.7 years. The sample included 11 subjects with autistic disorder, 3 with Asperger's disorder, 1 with childhood disintegrative disorder, and 3 with pervasive developmental disorder not otherwise specified. Fourteen subjects had comorbid mental retardation. Behavioral ratings were obtained during two baseline visits and again after 12 weeks of risperidone treatment. RESULTS: The optimal dose of risperidone for the 18 subjects was 1.8 +/- 1.0 mg/day. On the basis of the global improvement item of the Clinical Global Impression Scale, 12 of 18 subjects were considered responders. Significant improvement was seen in measures of interfering repetitive behavior, aggression and impulsivity, and some elements of impaired social relatedness. The most common side effect was weight gain (range 10 to 35 lb). CONCLUSIONS: These preliminary results suggest that risperidone may be effective for improving interfering behavioral symptoms in some children and adolescents with pervasive developmental disorders. Double-blind, placebo-controlled studies are needed before definitive statements of safety and efficacy can be made. SN - 0890-8567 UR - https://www.unboundmedicine.com/medline/citation/9136504/Risperidone_treatment_of_children_and_adolescents_with_pervasive_developmental_disorders:_a_prospective_open_label_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0890-8567(09)62836-7 DB - PRIME DP - Unbound Medicine ER -